CS
MRTX

Candriam SCA’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Candriam SCA’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-893,763
Closed -$38.9M – 731
2023
Q3 		$38.9M Buy
893,763
+20,000
+2% +$714K 0.28% 76
2023
Q2 		$31.6M Buy
873,763
+109,498
+14% +$4.51M 0.23% 113
2023
Q1 		$26.2M Sell
764,265
-3,331
-0.4% -$150K 0.18% 134
2022
Q4 		$34.8M Buy
767,596
+105,095
+16% +$6.8M 0.23% 101
2022
Q3 		$46.3M Buy
662,501
+68,217
+11% +$5.05M 0.33% 72
2022
Q2 		$39.9M Buy
594,284
+87,511
+17% +$5.57M 0.33% 75
2022
Q1 		$41.7M Buy
506,773
+14,290
+3% +$1.46M 0.28% 84
2021
Q4 		$72.2M Buy
492,483
+109,264
+29% +$17M 0.46% 51
2021
Q3 		$67.8M Buy
383,219
+37,623
+11% +$6.05M 0.46% 50
2021
Q2 		$55.8M Buy
345,596
+156,496
+83% +$25.1M 0.38% 57
2021
Q1 		$39.9M Buy
189,100
+2
+0% +$396 0.33% 72
2020
Q4 		$41.5M Buy
189,098
+55,961
+42% +$12.1M 0.33% 72
2020
Q3 		$22.1M Buy
133,137
+23,076
+21% +$3.16M 0.21% 125
2020
Q2 		$12.6M Buy
110,061
+10,733
+11% +$1.04M 0.13% 181
2020
Q1 		$12.5M Buy
99,328
+5
+0% +$448 0.14% 170
2019
Q4 		$12.8M Sell
99,323
-22,977
-19% -$2.22M 0.14% 171
2019
Q3 		$9.53M Sell
122,300
-34,700
-22% -$3.26M 0.13% 193
2019
Q2 		$16.1M Buy
157,000
+44,000
+39% +$3.43M 0.2% 115
2019
Q1 		$8.28M Sell
113,000
-98,000
-46% -$6.67M 0.11% 226
2018
Q4 		$8.95M Buy
211,000
+19,000
+10% +$757K 0.14% 176
2018
Q3 		$9.04M Buy
192,000
+99,300
+107% +$5.53M 0.12% 204
2018
Q2 		$4.57M Buy
+92,700
New +$3.5M 0.07% 311
2016
Q3 		– Sell
-70,000
Closed -$382K – 682
2016
Q2 		$382K Sell
70,000
-34,000
-33% -$542K 0.01% 600
2016
Q1 		$2.21M Sell
104,000
-11,000
-10% -$246K 0.06% 306
2015
Q4 		$3.63M Buy
115,000
+8,000
+7% +$283K 0.1% 222
2015
Q3 		$3.68M Sell
107,000
-3,000
-3% -$90.7K 0.09% 246
2015
Q2 		$3.46M Sell
110,000
-4,000
-4% -$118K 0.07% 289
2015
Q1 		$3.34M Buy
114,000
+44,000
+63% +$1.03M 0.07% 318
2014
Q4 		$1.3M Buy
+70,000
New +$1.18M 0.03% 414

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Candriam SCA's MRTX Position: Q4 2023 in Review

Candriam SCA sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 893,763 shares — an estimated $38.9M sold.

Candriam SCA first reported a position in MRTX in Q4 2014 and held it in 29 quarters. The position peaked at $72.2M in Q4 2021. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Candriam SCA reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Candriam SCA sold 893,763 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $38.9M.
  • Candriam SCA first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2014 and held it in 29 quarters.
  • Candriam SCA's Mirati Therapeutics, Inc. Common Stock position peaked at $72.2M in Q4 2021.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Candriam SCA's 13F filing for Q4 2023, filed 14 Feb 2024.